Abstract
Background: Surgical resection is the most effective treatment for colorectal liver metastases but only a minority of patients are candidates for a potentially curative resection. Our experience with neoadjuvant chemotherapy followed by resection and five years survival analysis of the patients treated is presented.
Methods: Between February of 1988 and September of 1996, 701 patients with unresectable colorectal liver metastases were treated with neoadjuvant chemotherapy. Four categories of nonresectable disease were defined: large size, ill location, multinodularity, and extrahepatic disease. Liver resection was performed in those patients whose disease became resectable. After resection, the patients were followed up every 3 months. A 5-year survival analysis by the different categories described was performed.
Results: Ninety-five patients (13.5%) were found to be resectable on reevaluation and underwent a potentially curative resection. There was no perioperative mortality, and the complication rate was 23%. As of December of 1999, 87 patients have completed 5 years of follow-up. The overall 5-year survival is 35% from the time of resection and 39% from the onset of chemotherapy. Respective 5-year survival rates are 60% for large tumors, 49% for ill-located lesions, 34% for multinodular disease, and 18% for liver metastases with extrahepatic disease. In this latter category, however, a 35% 5-year survival was found when all the patients with extrahepatic disease were analyzed rather than only those for whom extrahepatic disease was the main cause of nonresectability.
Conclusions: Neoadjuvant chemotherapy enables liver resection in some patients with initially unresectable colorectal metastases. Long-term survival is similar to that reported for a priori surgical candidates.
Similar content being viewed by others
References
Fong Y, Kemeny N, Paty P, et al. Treatment of colorectal cancer hepatic metastasis. Semin Surg Oncol 1996; 12: 219–52.
Steele G Jr, Ravikumar TS. Resection of hepatic metastases from colorectal cancer: biologic perspectives. Ann Surg 1989; 210: 127–38.
Weiss L, Grundmann E, Torhorst J, et al. Hematogenous metastatic patterns in colonic carcinoma: an analysis of 1541 necropsies. J Pathol 1986; 150: 195–203.
Fortner JG, Silva JS, Golbey RB, et al. Multi-variate analysis of a personal series of 247 consecutive patients with liver metastases from colorectal cancer. Ann Surg 1984; 199: 306–16.
Adson MA, Van Heerden JA, Adson MH, et al. Resection of hepatic metastases from colorectal cancer. Arch Surg 1984; 119: 647–51.
Hughes KS, Simon R, Songhorabodi S, et al. Resection of the liver for colorectal carcinoma metastases: a multi-institutional study of indications for resection. Surgery 1988; 103: 278–88.
Nordlinger B, Jaeck D, Guiguet M, et al. Traitement des metastases hepatiques des cancers colorectaux. Monographies de l’ Association Francaise de Chirurgie (AFC). 1992; 129–46. Paris, France: Springer Verlag,
Scheele J, Stang R, Altendorf-Hofmann A, et al. Resection of colorectal liver metastases. World J Surg 1995; 19: 59–71.
Fong Y, Cohen A, Fortner JG, et al. Liver resection for colorectal metastases. J Clin Oncol 1997; 15: 938–46.
Bismuth H, Adam R, Levi F, et al. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg 1996; 224: 509–22.
Adson MA, Resectionof liver metastases. When is it worthwhile? World J Surg 1987; 11: 511–20.
Doci R, Gennari L, Bignami P, et al. One hundred patients with hepatic metastases from colorectal cancer treated by resection: analysis of prognostic determinants. Br J Surg 1991; 78: 797–801.
Levi F, Misset JL, Brienza S, et al. A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid and oxaliplatin using an ambulatory multichannel programmable pump. Cancer 1992; 69: 893–900.
Azoulay D, Raccuia JS, Castaing D, et al. Right portal vein embolization in preparation for major hepatic resection. J Am Coll Surg 1995; 181: 267–9.
Fowler WC, Eisenberg BL, Hoffman JP. Hepatic resection following systemic chemotherapy for metastatic colorectal carcinoma. J Surg Oncol 1992; 51: 122–5.
Elias D, Lasser P, Rougier P, et al. Frequency, technical aspects, results and indications of major hepatectomy after prolonged intra-arterial hepatic chemotherapy for initially unresectable hepatic tumors. J Am Coll Surg 1995; 180: 213–9.
Giachetti S, Itzhaki M, Gruia G, et al. Long term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann Oncol 1999; 10: 663–9.
Becouarn Y, Ychou M, Ducreux M, et al. Oxaliplatin (L-OHP) as first line chemotherapy in metastatic colorectal cancer (MRC) patients: preliminary activity/toxicity report [Abstract]. Proc Am Soc Clin Oncol 1997; 16: 229A.
Levi F, Giacchetti S, Adam R, et al. Chronomodulation of chemotherapy against metastatic colorectal cancer. Eur J Cancer 1995; 31A: 1264–70.
Levi F, Zidani R, Brienza S, et al. A multicenter evaluation of intensified ambulatory chronomodulated chemotherapy with oxaliplatin, 5-fluorouracil and leucovorin as initial treatment of patients with metastatic colorectal carcinoma. Cancer 1999; 85: 2532–40.
Bertheault-Cvitkovic F, Jami.A, Ithzaki M, et al. Bi weekly intensified ambulatory chronomodulated chemotherapy with oxaliplatin, 5-fluorouracil and folinic acid in patients with metastatic colorectal cancer. J Clin Oncol 1996; 14: 2950–8.
Levi F, Zidani R, Vannetzel JM, et al. Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trial. J Natl Cancer Inst 1994; 86: 1608–17.
Levi F, Zidani R, Misset JL, et al. Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. Lancet 1997; 350: 681–6.
Murata S, Moriya Y, Akasu T, et al. Resection of both hepatic and pulmonary metastases in patients with colorectal carcinoma. Cancer 1998; 83: 1086–93.
Regnard JF, Grunenwald D, Spaggiari L, et al. Surgical treatment of hepatic and pulmonary metastases from colorectal cancers. Ann Thorac Surg 1998; 66: 214–9.
Author information
Authors and Affiliations
Corresponding author
Additional information
Dr. Avisar is currently at the Division of Surgical Oncology, University of Pittsburgh Medical Center, Pittsburgh Pennsylvania.
Rights and permissions
About this article
Cite this article
Adam, R., Avisar, E., Ariche, A. et al. Five-Year Survival Following Hepatic Resection After Neoadjuvant Therapy for Nonresectable Colorectal [Liver] Metastases. Ann Surg Oncol 8, 347–353 (2001). https://doi.org/10.1007/s10434-001-0347-3
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s10434-001-0347-3